A practical reference on RP-HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-07-22 and is reviewed periodically as new material appears.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
=== Thyroid cancer === The US Food and Drug Administration requires a boxed warning in the package inserts of GLP-1 agonists due to the risk of thyroid C-cell tumors, including medullary thyroid cancer (MTC). GLP-1 agonists are contraindicated in people with a family or personal history of MTC or multiple endocrine neoplasia type 2. In mice, long-term use of GLP-1 agonists stimulates calcitonin secretion, leading to C-cell hypertrophy and increased risk of thyroid cancer, but no increased secretion of calcitonin has been observed in humans. A retrospective national cohort study in France reported an increased risk of thyroid cancer (all and medullary) after 1–3 years of treatment with GLP-1 agonists for diabetes, but other large retrospective studies have not reported a similar association, including with long-term use of GLP-1 agonists and over 10 years of followup.
Epidermolysis bullosa (EB) is a group of rare medical conditions that result in easy blistering of the skin and mucous membranes. Blisters occur with minor trauma or friction and are painful. Its severity can range from mild to fatal. Inherited EB is a rare disease, with a prevalence of 8.2 per million live births in the United States as of November 2004. Those with mild cases may not develop symptoms until they start to crawl or walk during early childhood. Complications may include esophageal narrowing, squamous cell skin cancer, and the need for amputations. EB is due to a mutation in at least one of 16 different genes. Some types are autosomal dominant while others are autosomal recessive. The underlying mechanism is a defect in attachment between or within the layers of the skin. Loss or diminished function of type VII collagen leads to weakness in the structural architecture of the dermoepidermal junction (DEJ) and mucosal membranes. There are four main types: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB), and Kindler syndrome. The diagnosis is suspected based on symptoms and confirmed by skin biopsy or genetic testing. There is no cure for the condition. Management involves wound care, pain control, infection control, nutritional support, and the prevention and treatment of complications. About half a million people are affected globally. It occurs equally commonly in males and females.
In 1992, Eric Taub brought ibogaine to an offshore location close to the United States, where he began providing treatments and popularizing its use. In Costa Rica, Lex Kogan, another leading proponent, joined Taub in systematizing its administration. The two men established medically monitored treatment clinics in several countries. In 1981, an unnamed European manufacturer produced 44 kg of iboga extract. The entire stock was purchased by Carl Waltenburg, who distributed it under the name "Indra extract" and used it in 1982 to treat heroin addicts in the community of Christiania, Copenhagen. Indra extract was available for sale over the Internet until 2006, when the Indra web presence disappeared. Various products are currently sold in several countries as "Indra extract", but it is unclear if any of them are derived from Waltenburg's original stock. Ibogaine and related indole compounds are susceptible to oxidation over time. The National Institute on Drug Abuse (NIDA) began funding clinical studies of ibogaine in the United States in the early 1990s, including conducting a clinical study in 1993, but terminated the project in 1995 following the unexpected death of a female participant. Data demonstrating ibogaine's efficacy in attenuating opioid withdrawal in drug-dependent human subjects was published by Alper et al. in 1999. A cohort of 33 patients were treated with 6 to 29 mg/kg of ibogaine; 25 displayed resolution of the signs of opioid withdrawal from 24 hours to 72 hours post-treatment, but one 24-year-old female, who received the highest dosage, died.
== Other uses == The nutrition-rich nature of yeast extract lends it to a variety of uses. It was historically popular as a vitamin supplement for humans. Rich in proteins and nucleotides, it currently finds use in animal feed and microbiology (see yeast extract agar) as nutritional supplements. It also finds use in cosmetics and skincare products due to its alleged moisturizing and antioxidant properties.
Sources: en.wikipedia.org
== Disorders == Platelet disorders can occur because there are not enough platelets, too many platelets, or the platelets do not function properly. Low platelet concentration is called thrombocytopenia, and is due to either decreased production, increased destruction of platelets, or platelets being sequestered in another part of the body. Elevated platelet concentration is called thrombocytosis, and is either congenital, reactive (to cytokines), or due to unregulated production: one of the myeloproliferative neoplasms or certain other myeloid neoplasms. Normal platelets can respond to an abnormality on the vessel wall rather than to hemorrhage, resulting in inappropriate platelet adhesion/activation and thrombosis: the formation of a clot within an intact vessel. This type of thrombosis arises by mechanisms different from those of a normal clot: extending the fibrin of venous thrombosis; extending an unstable or ruptured arterial plaque, causing arterial thrombosis; and microcirculatory thrombosis. An arterial thrombus may partially obstruct blood flow, causing downstream ischemia, or may completely obstruct it, causing downstream tissue death.:
As relations between Washington and Moscow improved, both governments increasingly worked to restrain their respective regional allies—pressuring their former proxies to make peace with one another—and establish negotiated settlements instead, while the US concomitantly stressed market globalization. In southern Africa, Soviet and Cuban support for the Angolan government diminished as diplomacy advanced, while the United States reduced backing for anti-communist insurgents, enabling peace processes that culminated in the late 1980s. Overall, this détente which accompanied the final twilight of the Cold War would help bring about a relatively more peaceful international environment. As a consequence of the Revolutions of 1989 and the adoption of a foreign policy based on non-interference by the Soviet Union, the Warsaw Pact rapidly lost its political and military rationale and began to dissolve. Meanwhile, troops stationed across eastern Europe began returning to the Soviet Union, completing their withdrawal by the mid-1990s. This marked the end of the Soviet military presence that had defined the political order in Europe since 1945. For all the complexity and geopolitical strain that the great power competition of the Cold War brought onto Europe during the second half of the 20th century, its trajectory turned out to be both "more prosperous and peaceful for Europeans than the first," so quips German historian Konrad Jarausch.
=== FEMA === In April, the Federal Emergency Management Agency denied an extension of benefits for areas in Georgia and North Carolina which had been hit by Hurricane Helene in September 2024. Tornadoes hit parts the state of Mississippi in March and a major disaster declaration by the federal government took more than two months, even at the request of Republican governor Tate Reeves of Mississippi. On May 23, the Trump administration approved disaster aid for areas within 8 states including Mississippi, as well as Nebraska, Iowa, Missouri, Kansas, Arkansas, Oklahoma, and Texas.
== Other species == Vernix was thought to be unique to human fetal development. In 2018, vernix-like material was reportedly obtained from pups of the California sea lion. Mass spectrometry of the material showed it to be fundamentally the same as human vernix, in both BCFA (branch-chain fatty acids) and squalene content. The presence of vernix throughout the infant gastro-intestinal tract, as well as in the meconium (first excretion), in both human and sea lion neonates, argues that the function of vernix may not be as an external skin protection, as often described in the literature, but as a preparation of the newborn GI tract against water-borne bacteria. As such, vernix caseosa, not present in any terrestrial mammal, including other primates, is one of several arguments for a possible semi-aquatic past of our ancestors.
=== Filming === England's Shepperton Studios and Ardmore Studios in Ireland and were used for the shooting of interior scenes, with most of the external West Berlin scenes shot in Dublin. A recreation of Checkpoint Charlie was constructed in Dublin's Smithfield Plaza. The exterior scenes in the East German Alps were filmed at Garmisch-Partenkirchen in Bavaria, West Germany. Scenes were filmed in the Netherlands in Noordwijk and at Amsterdam Airport Schiphol. The remainder of the film was shot in London, at several locations including HM Prison Wormwood Scrubs, Battersea Park, and Trafalgar Square. The exterior of George Smiley's safe house was located at 19 Bramerton Street in Chelsea. Richard Burton demanded that Le Carré rewrite his dialogue on the set, though the effect of his changes were limited. Le Carré opined in his autobiography The Pigeon Tunnel: Stories from My Life that Burton had mostly wanted him there as a drinking buddy, and to mediate his clashes with Ritt. "Burton was a literate, serious artist, a self-educated polymath with appetites and flaws that in one way or another we all share," he wrote of their relationship.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.